<DOC>
	<DOCNO>NCT00791713</DOCNO>
	<brief_summary>The purpose study evaluate effect CYP2D6 inhibitor , paroxetine , pharmacokinetics single dose orally administer paliperidone ER evaluate safety tolerability treatment healthy men</brief_summary>
	<brief_title>A Study Effects Paroxetine Pharmacokinetics Paliperidone ER</brief_title>
	<detailed_description>This randomize , open-label , single-center , single-dose , 2 treatment , 2 way crossover study . It consist 3 phase : screen phase begin within 21 day first study drug administration ; open label treatment phase consist 2 treatment period ( Period 1 Period 2 ) , patient receive 2 single dos 3 mg paliperidone ER ; end study evaluation upon completion study procedure Period 2 early withdrawal . All volunteer receive follow 2 treatment random order : Treatment A : 1 tablet 3 mg paliperidone ER fast state ; Treatment B : one 20 mg paroxetine tablet day Day 1 Day 13 1 tablet 3 mg paliperidone ER Day 10 fast state . Successive paliperidone ER administration separate washout period least 14 day 28 day . Paroxetine potent selective CYP2D6 inhibitor . Inhibitors CYP2D6 paroxetine report increase plasma concentration antipsychotic perphenazine , clozapine , risperidone . Because paliperidone ER paroxetine could potentially use combination schizophrenic patient , potential drug-drug interaction paroxetine paliperidone ER need explored.The safety tolerability 3 mg tablet paliperidone ER administer without paroxetine healthy men monitor . Two single oral dos paliperidone ER 3-mg ; 20-mg paroxetine orally day 13 day</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Body mass index ( weight [ kg ] /height [ m2 ] ) 18 30 kg/m2 , inclusive Extensive metabolizer CYP2D6 . Volunteers whose CYP2D6 genotype unknown phenotyped start study use dextromethorphan probe ( i.e. , dextromethorphan metabolic ratio &lt; 0.02 , determine accord standard procedure study center ) Have supine ( 5 minute rest ) blood pressure 100 140 mmHg systolic , inclusive , 50 90 mmHg diastolic , inclusive Smokes 10 cigarette , 2 cigar , 2 pipe per day follow pattern least 3 month screen Healthy basis prestudy physical examination , medical history , 12lead ECG , laboratory result serum chemistry , hematology , urinalysis perform within 21 day first dose . If result serum chemistry , hematology , urinalysis test within laboratory 's reference range , volunteer include investigator judge deviation clinically significant . For renal function test , value must within normal laboratory reference range Poor intermediate metabolizers CYP2D6 , determine genotyping phenotyping use dextromethorphan Known drug allergy risperidone , paliperidone , paroxetine , excipients Known history druginduced dystonia Recent history alcohol substance abuse Relevant history presence cardiovascular ( include myocardial infarct cardiac arrhythmia ) , respiratory , neurologic ( include seizure ) , psychiatric , renal , hepatic , gastrointestinal ( include surgery , severe gastrointestinal narrowing , malabsorption problem ) , endocrine , hematologic , immunologic disease History cancer , exception basal cell carcinoma At screening , sign autonomic dysfunction indicate sustained decrease &gt; 20 mmHg systolic blood pressure decrease &gt; 10 mmHg diastolic blood pressure stand least 2 minute associated increase &gt; 15 beat per minute ( bpm ) heart rate Bradycardia ( heart rate &lt; 50 bpm ) determine screen 12lead ECG A positive test result ( history ) serology test ( hepatitis B C , human immunodeficiency virus ) screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Paliperidone ER</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Selective serotonin reuptake inhibitor</keyword>
	<keyword>Mood disorder</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>